Contribute Try STAT+ Today

The Food and Drug Administration on Thursday approved Roche’s cancer drug Rozlytrek for patients with any kind of tumor that tests positive for one kind of genetic alteration, known as NTRK, and for non-small cell lung cancer that tests positive for another genetic alteration, ROS1.

It’s the third time that the FDA has approved a cancer drug not based on where the tumor showed up in the body but on its genetic makeup. It’s part of an emerging picture of the future of cancer treatment — one that has been long imagined.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.